Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Psoriasis and the new biologic agents: interrupting a T-AP dance Walsh SR; Shear NHCMAJ 2004[Jun]; 170 (13): 1933-41Psoriasis is an immune-mediated skin disease in which chronic T-cell stimulation by antigen-presenting cells (APC) occurs in the skin. This interplay between the T-cell and APC has been likened to a "T-AP dance" where specific steps must occur in sequence to result in T-cell activation and the disease phenotype; otherwise T-cell anergy would occur. Several novel engineered proteins designed to block specific steps in immune activation (biologic agents) have demonstrated efficacy in the treatment of psoriasis. These agents include fusion proteins, monoclonal antibodies and recombinant cytokines. These medications act at specific steps during the T-AP dance either to inhibit T-cell activation, costimulation and subsequent proliferation of T-cells, lead to immune deviation or induce specific cytokine blockades. The potential increased selectivity for specific pathways in immune activation, clinical efficacy and relative safety of these new agents offers an alternative for the treatment of moderate to severe psoriasis.|Antibodies, Monoclonal/*pharmacology/therapeutic use[MESH]|Antigen-Presenting Cells/drug effects/immunology[MESH]|Cytokines/*pharmacology/therapeutic use[MESH]|Humans[MESH]|Lymphocyte Activation/drug effects/immunology[MESH]|Psoriasis/*immunology/*therapy[MESH]|Recombinant Fusion Proteins/*pharmacology/therapeutic use[MESH]|Recombinant Proteins/pharmacology/therapeutic use[MESH]|T-Lymphocytes/drug effects/immunology[MESH] |
